Status:

UNKNOWN

Short-course Radiotherapy With Induction and Consolidation Chemotherapy in Patients With Locally Advanced Rectal Cancer

Lead Sponsor:

Instituto Nacional de Cancer, Brazil

Conditions:

Rectal Cancer

Total Neoadjuvant Treatment

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

Short-course radiotherapy followed by consolidation chemotherapy has shown a better response rate when compared to chemoradiotherapy treatment. In addition, recent studies have shown better tolerance...

Detailed Description

Methods: This trial aim to evaluate induction treatment with CAPOX, followed by short-course radiotherapy consolidation chemotherapy with CAPOX. After 5-7 weeks, patients will be evaluate by MRI. Pati...

Eligibility Criteria

Inclusion

  • Histologically confirmed adenocarcinoma of mid or low rectum
  • Locally advanced rectal cancer with one of the high-risk factors confirmed by high-resolution thin-slice Magnetic resonance image (3 mm) tumors extending to within 1 mm of, or beyond the mesorectal fascia; tumor extending 5 mm or more into perirectal fat; resectable cT4 tumors; lower third; nodal involvement; extramural vascular invasion
  • ECOG performance status of 0-2
  • An informed consent has been signed by the patient

Exclusion

  • Upper rectal cancer
  • Metastatic disease
  • The patient received any previous therapy for colorectal cancer or another malignancy
  • Other malignant tumours within the last 5 years except cervical carcinoma in situ and basal cell carcinoma of the skin
  • Previous thromboembolic or haemorrhagic events within 6 months prior to registration
  • Patients with malabsorption syndrome or difficulties in swallowing
  • The patient has severe underlying diseases or poor condition to receive chemotherapy or radiotherapy
  • Pregnant of breastfeeding women
  • The patient who participate in another clinical trial, or receives any drug for the trial
  • Uncontrolled peripheral neuropathy (more than grade 2)

Key Trial Info

Start Date :

November 10 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2022

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT04674696

Start Date

November 10 2020

End Date

June 1 2022

Last Update

December 19 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

INCA- Instituto Nacional de Câncer

Rio de Janeiro, Brazil, 20231-050